XOMA Co. (NASDAQ:XOMAO – Get Free Report) was the target of a large decline in short interest in April. As of April 30th, there was short interest totaling 290 shares, a decline of 89.8% from the April 15th total of 2,830 shares. Based on an average daily volume of 8,328 shares, the days-to-cover ratio is currently 0.0 days.
XOMA Trading Down 0.1%
XOMA stock traded down $0.03 during mid-day trading on Monday, hitting $25.27. The company’s stock had a trading volume of 2,790 shares, compared to its average volume of 3,979. XOMA has a twelve month low of $24.86 and a twelve month high of $26.40. The stock’s fifty day moving average price is $25.49 and its two-hundred day moving average price is $25.43.
XOMA Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Thursday, April 2nd were paid a $0.5234 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.09 dividend on an annualized basis and a yield of 8.3%.
About XOMA
XOMA Corporation is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic antibodies. The company applies its proprietary protein engineering and antibody optimization platform to generate novel drug candidates targeting autoimmune, inflammatory and metabolic diseases. XOMA’s scientific expertise spans antibody discovery, engineering, in vitro and in vivo testing, and early‐stage clinical development.
In addition to advancing its own pipeline of antibody candidates, XOMA collaborates with pharmaceutical and biotechnology partners to provide research and development services.
Recommended Stories
- Five stocks we like better than XOMA
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.
